Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16975542 | 1.00 | LRRK2 (0.53) | LRRK2DYRK1AKCNH2KAT2BMAP3K12 | |
| SCHEMBL16985433 | 1.00 | LRRK2 (0.53) | LRRK2DYRK1AKCNH2KAT2BMAP3K12 | |
| SCHEMBL16985357 | 1.00 | LRRK2 (0.53) | LRRK2DYRK1AKCNH2KAT2BMAP3K12 | |
| SCHEMBL21958470 | 0.86 | LRRK2 (0.54) | LRRK2DYRK1AKCNH2KAT2B | |
| SCHEMBL24271370 | 0.85 | LRRK2 (0.42) | LRRK2DYRK1AKCNH2KAT2BMAP3K12 | |
| SCHEMBL21610987 | 0.85 | LRRK2 (0.55) | LRRK2DYRK1AKCNH2KAT2B | |
| SCHEMBL21821365 | 0.85 | LRRK2 (0.46) | LRRK2DYRK1AKCNH2KAT2BMAP3K12 | |
| SCHEMBL16985343 | 0.85 | LRRK2 (0.46) | LRRK2DYRK1AKCNH2KAT2BMAP3K12 | |
| SCHEMBL21938979 | 0.84 | LRRK2 (0.42) | LRRK2DYRK1AKCNH2 | |
| SCHEMBL21954900 | 0.82 | LRRK2 (0.53) | LRRK2DYRK1AKCNH2KAT2BMAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| EP-3099695-B1 | COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-04-08 | — | — | EP | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2015113452-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | LRRK2, PARK7, PINK1 | LRRK2 1/4885DYRK1A 1061/4885KCNH2 3594/4885 |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LRRK2 1/4885DYRK1A 142/4885KCNH2 1965/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LRRK2 1/4885DYRK1A 141/4885KCNH2 1736/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LRRK2 1/4885DYRK1A 142/4885KCNH2 1965/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | LRRK2 1/4885DYRK1A 136/4885KCNH2 2115/4885 |
| US-20170015668-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | LRRK2 1/4885DYRK1A 2308/4885KCNH2 3477/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | LRRK2 1/4885DYRK1A 136/4885KCNH2 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.